



FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS

TOTAL COMPANY

WORLDWIDE SALES

Q4 **\$11.5B**

FULL YEAR **\$43.1B**

FULL YEAR **\$5.21³**
ADJUSTED
DILUTED EPS

GROWTH ON AN ORGANIC BASIS*

Q4 **+7.7%¹**

FULL YEAR **+22.9%²**

REFLECTS NEARLY

43%⁴

GROWTH VERSUS
PRIOR YEAR

BUSINESS HIGHLIGHTS

LEADING IN HEALTH TECH

► **\$1.0B** Q4 FREESTYLE
LIBRE[®] SALES

Now approaching 4 million users globally


► **15.8%⁸** GROWTH IN
MEDICAL DEVICES
on an organic basis* compared to
pre-pandemic sales in 2019



FULL-YEAR 2021: KEY BUSINESS UNITS⁵ GROWTH ON AN ORGANIC BASIS*

 **+19.4%**
MEDICAL DEVICES

 **+42.7%**
DIAGNOSTICS

 **+7.7%**
NUTRITION

 **+10.4%**
ESTABLISHED
PHARMACEUTICALS

ADVANCING OUR R&D PIPELINE

- New product introductions and approvals across our portfolio, including several in large, fast-growing markets
- Highlights include expanded reimbursement coverage for MitraClip[®] and launch of NeuroSphere[™] Virtual Clinic for remote treatment chronic pain or movement disorders

NEUROSPHERE[™]
VIRTUAL CLINIC



STEPPING UP ON TESTING

- More than 1.4 billion COVID tests distributed globally since the start of the pandemic
- Excluding COVID-19 testing-related sales, fourth-quarter Diagnostics sales increased 8.7%⁹ on an organic basis*



ISSUED FULL-YEAR 2022 EPS GUIDANCE

AT LEAST

\$4.70⁶
IN ADJUSTED
DILUTED EPS

REFLECTS

45%⁷
GROWTH
COMPARED
TO 2019

*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press releases dated Jan. 26, 2022, available at www.abbottinvestor.com. 1. On a GAAP basis, fourth-quarter Abbott sales increased 7.2%. 2. On a GAAP basis, full-year 2021 Abbott sales increased 24.5%. 3. Full-year 2021 GAAP diluted EPS from continuing operations was \$3.94. 4. Full-year 2021 diluted EPS from continuing operations on a GAAP basis reflects 58% growth. 5. On a GAAP basis, full-year 2021 Medical Devices sales increased 21.9%; Diagnostics sales increased 44.8%; Nutrition sales increased 8.5%; Established Pharmaceuticals sales increased 9.6%. 6. Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least \$3.43. Abbott forecasts specified items for the full-year 2022 of \$1.27 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least \$4.70 for the full-year 2022. 7. On a GAAP basis, full-year 2022 projected adjusted diluted EPS from continuing operations reflects 67% growth compared to 2019. Full-year 2019 diluted EPS from continuing operations was \$2.06 on a GAAP basis and \$3.24 on an adjusted basis. 8. On a GAAP basis, Medical Devices full-year 2021 sales increased 17.0% compared to sales in 2019. 9. On a GAAP basis excluding COVID-19 testing-related sales, fourth-quarter Diagnostics sales increased 8.2%. †Find important safety information about the FreeStyle[®] Libre portfolio: www.freestylelibre.us/safety-information.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.